Alterity Therapeutics Featured at International MSA Congress
Ticker: PRNAF · Form: 6-K · Filed: May 12, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | May 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: reporting, conference, registration-statement
TL;DR
Alterity Therapeutics highlighted at international MSA conference, filing incorporated into existing SEC registrations.
AI Summary
Alterity Therapeutics Ltd. filed a Form 6-K on May 12, 2025, to report its activities for May 2025. The filing incorporates by reference into several of its S-8 and F-3 registration statements. Exhibit 99.1 highlights Alterity's prominent feature at the International MSA Congress.
Why It Matters
This filing indicates ongoing engagement and visibility for Alterity Therapeutics within the medical community, specifically concerning Multiple System Atrophy (MSA).
Risk Assessment
Risk Level: low — The filing is a routine report of foreign private issuer activities and does not contain new financial or operational disclosures that would significantly alter risk.
Key Players & Entities
- ALTERITY THERAPEUTICS LTD (company) — Registrant
- International MSA Congress (event) — Event where Alterity was featured
- PRANA BIOTECHNOLOGY LTD (company) — Former company name
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is a Report of Foreign Private Issuer for the month of May 2025, and it incorporates by reference into Alterity Therapeutics' existing Registration Statements on Form S-8 and Form F-3.
What is the significance of Exhibit 99.1 mentioned in the filing?
Exhibit 99.1 states that Alterity Therapeutics was prominently featured at the International MSA Congress.
When was Alterity Therapeutics Limited formerly known as?
Alterity Therapeutics Limited was formerly known as PRANA BIOTECHNOLOGY LTD, with a name change date of January 5, 2001.
Where is Alterity Therapeutics Limited's principal executive office located?
Alterity Therapeutics Limited's principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Which SEC registration statements does this 6-K filing get incorporated into?
This Form 6-K is incorporated by reference into Alterity's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on May 12, 2025 regarding ALTERITY THERAPEUTICS LTD (PRNAF).